Beam Therapeutics (BEAM) to Release Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.13) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 7:00 AM ET.

Beam Therapeutics Stock Performance

Beam Therapeutics stock opened at $27.92 on Tuesday. The company’s 50 day simple moving average is $28.57 and its 200-day simple moving average is $24.56. Beam Therapeutics has a 1 year low of $13.52 and a 1 year high of $36.44. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -6.30 and a beta of 2.12.

Insider Activity at Beam Therapeutics

In related news, insider Christine Bellon sold 18,629 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $34.61, for a total transaction of $644,749.69. Following the sale, the insider directly owned 97,038 shares in the company, valued at approximately $3,358,485.18. This represents a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC increased its position in shares of Beam Therapeutics by 4,370.5% in the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock valued at $48,000 after purchasing an additional 1,923 shares during the last quarter. Kestra Advisory Services LLC acquired a new position in shares of Beam Therapeutics during the fourth quarter worth $59,000. Van ECK Associates Corp increased its holdings in Beam Therapeutics by 48.7% in the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after buying an additional 707 shares during the last quarter. IFC & Insurance Marketing Inc. acquired a new stake in Beam Therapeutics in the fourth quarter valued at $69,000. Finally, CIBC Private Wealth Group LLC lifted its holdings in Beam Therapeutics by 46.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,144 shares of the company’s stock worth $87,000 after buying an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Wall Street Analyst Weigh In

BEAM has been the topic of a number of research analyst reports. UBS Group initiated coverage on Beam Therapeutics in a research report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 target price on the stock. Sanford C. Bernstein boosted their price objective on Beam Therapeutics from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Wall Street Zen cut Beam Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, January 21st. Finally, Tudor Pickering set a $41.00 price target on shares of Beam Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.80.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.